Marilyn Huang, MD
Gynecologic Oncology · Charlottesville, VANPI 1982856175
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $33,690 of the $39,195 with a category attached, or 86.0%. It is spread thinly across 15 manufacturers, the largest accounting for just 20.8%.
Across 56 payments — averaging $699.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$8K
- Seagen Inc.$8K
- Coopersurgical, Inc.$4K
- Tesaro, Inc.$4K
- Eisai Inc.$3K
- GSK$3K
- plus $9K from 9 others
Across 86 payments — averaging $43,340 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$3.2M
- AbbVie$272K
- Pfizer$101K
- GSK$92K
- Roche Products Limited$63K
- Seagen Inc.$21K
- plus $15K from 2 others
What the payments were for
- Consulting fees$33,69086%
- Speaking & faculty fees$1,5754%
- Travel & lodging$1,9475%
- Food & beverage$1,8985%
- Education$850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 5 | $8,162 |
| Seagen Inc. | 6 | $8,120 |
| Coopersurgical, Inc. | 3 | $4,275 |
| Tesaro, Inc. | 9 | $4,229 |
| Eisai Inc. | 2 | $3,269 |
| GSK | 4 | $2,523 |
| AstraZeneca | 7 | $1,851 |
| Pfizer | 2 | $1,771 |
| Immunogen, Inc. | 3 | $1,594 |
| Clovis Oncology, Inc. | 4 | $1,585 |
| Karyopharm Therapeutics Inc. | 5 | $1,431 |
| AbbVie | 2 | $188 |
| Myriad Genetic Laboratories, Inc. | 2 | $119 |
| Puma Biotechnology, Inc. | 1 | $76 |
| Intuitive Surgical | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TIVDAK$6,046
- LENVIMA$3,269
- Advincula Delineator Uterine Manipulator$2,850
- JEMPERLI$2,400
- Elahere$1,653
- Rubraca$1,500
- LYNPARZA$1,470
- Uterine Manipulators & Injectors$1,425
- XPOVIO$1,342
How this compares
$39,195 in reported general payments places this provider in the 85th percentile of 47 gynecologic oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 16 | $77 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Charlottesville
- Samantha BatmanCharlottesville$76K
- Linda DuskaCharlottesville$72K
- Kari RingCharlottesville$14K
- Susan ModesittCharlottesville$4K
- Charles LandenCharlottesville$3K
- Leigh CantrellCharlottesville$460
- Jaime KiffCharlottesville$82
- Cecelia BoardmanRichmond$577K
- Leslie RandallFairfax$342K
- Chad HamiltonAnnandale$242K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.